Causes and Risk Factors of Kaposi's Sarcoma

Table of Contents
View All
Table of Contents

Immunosuppression (the partial or complete lack of an immune response) and an infection with a human herpesvirus 8 (HHV8) virus is the ultimate cause of Kaposi's sarcoma (KS). It is most commonly associated with advanced human immunodeficiency virus (HIV) but has other forms that affect different populations.

This article looks at the causes of the different types of Kaposi's sarcoma and which factors place you at an increased risk of this rare form of cancer.

Healthcare provider consoles person with AIDS and Kaposi sarcoma

Khaosai Wongnatthakan / Getty Images

Common Causes

Kaposi's sarcoma can only occur in people with HHV8 (also known as Kaposi's sarcoma-associated herpesvirus, or KSHV). The virus, which is closely related to the Epstein-Barr virus (EBV), is mainly passed from person to person through saliva. But unlike EBV, repeated exposure is generally needed.

HHV8 is relatively rare in the United States, affecting between 1% and 3% of the general population. By contrast, between 10% and 20% of people living in certain Mediterranean countries and 30%–80% of those living in parts of sub-Saharan Africa have HHV8.

There are six major subtypes of HHV8—subtypes A, B, C, D, E, and F—some of which are confined to specific geographic regions. It is thought that some of these subtypes may be more aggressive than others, but the evidence of this is limited. There is also no clear association between an HHV8 subtype and any specific type of KS.

Ongoing Infection

Once you have been infected with HHV8, you will never get rid of it. The virus itself cannot be cured.

Having HHV8 does not mean that you will get KS. This is because HHV8 is opportunistic, meaning that it can only cause disease when the immune system has been weakened. When this happens, the dormant virus will suddenly activate, causing tumors on the skin and mucous membranes that appear as purplish lesions or nodules.

The underlying cause of immunosuppression differs by the type of KS a person has.

HIV-Associated Kaposi's Sarcoma

HIV-associated Kaposi's sarcoma, sometimes referred to as epidemic KS or AIDS-related KS, typically occurs when HIV is advanced and a person's immune system is compromised. Unlike certain forms of KS, it tends to be quite aggressive.

HIV causes disease by targeting and killing immune cells known as CD4 T cell lymphocytes. As more and more of these cells are destroyed, the immune system becomes less and less able to defend itself against otherwise harmless infections.

KS tends to affect people with AIDS (acquired immune deficiency syndrome), the most advanced stage of HIV infection. AIDS is defined in part by a blood test known as a CD4 count. A normal CD4 count is between 500 and 1,500 cells per cubic milliliter of blood (cells/mm3). A person is said to have AIDS when the CD4 count drops below 200.

Even so, KS can and does occur at CD4 counts above 200.

Men who have sex with men (MSM) with HIV are 3 times more likely to have KS than other people living with the disease. This is due in part to the high rate of HIV among MSM—not only in the United States but globally.

Classic Kaposi's Sarcoma

Classic Kaposi's sarcoma is a slowly progressing form of KS that mainly affects older men of Mediterranean or Eastern European descent. Jewish, Greek, and Italian men are most predominantly affected.

Unlike KS in people with HIV, which can spread to internal organs, classic KS is rarely aggressive and tends to be limited to the lower legs and hands. Even oral lesions in the mouth and gums are uncommon.

Beyond sex and ethnicity, the overriding risk factor for classic KS is age. Studies suggest that the average age of diagnosis of people with classic KS is 69 years (although some only develop the disease in their 90s).


Aging plays a central role in classic KS in that it is associated with a natural decline in immune function.

Transplant-Related Kaposi's Sarcoma

Transplant-related Kaposi's sarcoma, sometimes called immunosuppression-associated KS or iatrogenic KS, affects organ transplant recipients on immunosuppressant drugs. Immunosuppressants are drugs used to prevent organ transplant rejection (in which the body regards donated organs as foreign and launches an immune assault).

The rate of transplant-related KS varies by how common HHV8 is in a geographic population. In some cases, a person may have HHV8 before undergoing a transplant, while others may get HHV8 from the donor organ.

More often than not, having HHV8 before a transplant increases the risk of developing KS.

As with classic KS, transplant-related KS tends to affect the lower limbs and will typically clear once the immunosuppressant drug is stopped. While it is uncommon for transplant-related KS to spread to internal organs, the prognosis (expected outcome) is generally poor if it does.

According to a 2018 analysis in the International Journal of Cancer, the risk factors for transplant-related KS include:

It is also seen more often in people who are not White.

Endemic Kaposi's Sarcoma

Endemic Kaposi's sarcoma is mainly confined to sub-Saharan Africa. The two types that differ not only by how aggressive they are but also by the population they affect are:

  • African lymphadenopathic Kaposi;s sarcoma is an aggressive form of KS that mainly affects children under age 10. It typically causes tumors on the lymph nodes that may or may not be accompanied by skin lesions. When both the skin and internal organs are involved, the risk of death is high, usually occurring within two months.
  • African cutaneous Kaposi's sarcoma mostly affects men between the ages of 20 and 50. It causes large nodules on the lower extremities that can progress rapidly, clear spontaneously, or remain stable for many years. Although it is less likely to affect internal organs, the lesions can sometimes bleed or form ulcers.

For reasons unknown, people of sub-Saharan African descent appear to be more susceptible to KS if they have HHV8. Unlike the other forms of KS, endemic KS can affect people whose immune function is impaired but is still largely intact.

It is thought that malnutrition and multiple chronic illnesses are risk factors for endemic KS. Certainly compared with other parts of the world, Africa faces more serious health concerns and a heavier burden of diseases, which may account for the increased susceptibility and lower immune response.


To date, it is unclear how much or little genetics contributes to the risk of Kaposi's sarcoma. With that said, there is some evidence that classic KS may be passed down in families.

Although the condition—referred to as familial KS—is rare, a 2014 study published in Case Reports in Dermatological Medicine identified five such cases in Greece.

In each of the five cases, two family members developed KS, none of whom had HIV. Interestingly, not only were male family members affected but also female family members in some cases. Most cases developed after the age of 50.

   Family Member  Age at Diagnosis  Age at Onset of Symptoms
Family 1 Father 78 60
  Son 36 33
Family 2 Mother 72 71
  Son 51 51
Family 3 Sister 72 69 
  Sister 51 51
Family 4 Brother 79 79
  Brother 65 64
Family 5 Father 75 73
  Son 57 57

While this is by no means proof of a genetic link, it does suggest that genetics and environment may play a part in the risk of KS in tandem with immune suppression and HHV8 infection.

Lifestyle Risk Factors

It is hard to suggest that there are any lifestyle factors that can reduce a person's risk of KS given that the risk factors—age, sex, ethnicity, etc.—are largely unmodifiable.

The one exception is the use of antiretroviral therapy in people with HIV. Antiretroviral drugs work by preventing the virus from making copies of itself. By doing so, the virus is suppressed to levels at which it can do the body little harm, allowing the immune system to gradually rebuild itself.

Untreated HIV

Arguably the biggest risk factor for HIV-associated KS is untreated HIV. Compared to people on antiretroviral therapy, people with untreated HIV are nearly 7 times more likely to get KS,

Given that KS is more common in people with AIDS, the early diagnosis and treatment of HIV are essential to preserving a person's immune function. Delaying treatment until the CD4 count is very low makes it all the more difficult to restore the CD4 count to normal or near-normal levels.


Kaposi's sarcoma (KS) is an uncommon form of cancer that affects the skin and mucous membranes of the gastrointestinal tract and, in rare cases, the lymph nodes and lungs. KS is due to the combination of immune suppression and infection with the human herpesvirus 8 (HHV8).

While KS is most commonly associated with HIV infection (HIV-associated KS), it can also affect organ transplant recipients (transplant-related KS), older men of Mediterranean or Eastern Europe descent (classic KS), and vulnerable children and younger men in Africa (endemic KS).

There are different risk factors for each of the four different KS types. Genetics and environmental factors may also play a part, although further research is needed.

A Word From Verywell

Kaposi's sarcoma is of serious concern as it is most often associated with advanced HIV infection. In some cases, it may even be the first sign of HIV. This is especially true given that 13% of 1.2 million people living with HIV in the United States are undiagnosed.

Antiretroviral therapy not only shrinks KS tumors but prevents them from spreading to internal organs. By getting diagnosed and treated early, you are not only less likely to experience serious HIV-associated illnesses like KS but more likely to live a normal, healthy life span.

Frequently Asked Questions

  • How do you get human herpesvirus 8 (HHV8)?

    Human herpesvirus 8 (HHV8), the virus linked to Kaposi's sarcoma, is mainly passed through saliva but is harder to pass than its cousin, the Epstein-Barr virus (which causes mononucleosis).

    In the United States, between 1% and 3% of the population has HHV8. By contrast, nearly one in four younger HIV-positive men who have sex with men (MSM) has HHV8.

  • Can you get Kaposi's sarcoma without HIV?

    Yes, but HIV remains the leading cause of Kaposi's sarcoma (KS) worldwide. Although KS can affect other groups (such as organ transplant recipients and older males of Mediterranean or Eastern European descent), your healthcare provider will still want to test you for HIV to ensure that you get the proper diagnosis and treatment.

  • At what CD4 count are you at risk for Kaposi's sarcoma?

    You can get Kaposi's sarcoma (KS) at any CD4 count. With that said, KS is more common at CD4 counts below 200. According to a 2014 study in the journal Cancer, the risk of KS is seven times greater at CD4 counts between 100 and 199 than at CD4 counts over 500. At CD4 counts below 50, the risk is 25 times greater.

18 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers. 2019;5(1):9. doi:10.1038/s41572-019-0060-9

  2. Schneider JW, Dittmer DP. Diagnosis and treatment of Kaposi sarcoma. Am J Clin Dermatol. 2017;18(4):529–39. doi:10.1007/s40257-017-0270-4

  3. Human herpesvirus-8 disease: epidemiology.

  4. Grabar S, Costagliola D. Epidemiology of Kaposi’s sarcoma. Cancers (Basel). 2021;13(22):5692. doi:10.3390/cancers13225692

  5. Naif HM. Pathogenesis of HIV infectionInfect Dis Rep. 2013;5(Suppl 1):e6. doi:10.4081/idr.2013.s1.e6

  6. Liu Z, Fang Q, Zuo J, Minhas V, Wood C, Zhang T. The world-wide incidence of Kaposi's sarcoma in the HIV/AIDS era. HIV Med. 2018;19(5):355-64. doi:10.1111/hiv.12584

  7. Altunay I, Kucukunal A, Demirci GT, Ates B. Variable clinical presentations of classic Kaposi sarcoma in Turkish patients. J Dermatol Case Rep. 2012;6(1):8–13. doi:10.3315/jdcr.2012.1088

  8. Cetin B, Aktash B, Bal O, et al. Classic Kaposi's sarcoma: a review of 156 cases. Dermatologica Sinica. 2018;36(4):185-9. doi:10.1016/j.dsi.2018.06.005

  9. Cahoon EK, Linet MS, Clarke CA, Pawlish KS, Engels EA, Pfeiffer RM. Risk of Kaposi sarcoma after solid organ transplantation in the United States. Int J Cancer. 2018;143(11):2741-8. doi:10.1002/ijc.31735

  10. Raeisi D, Payandeh M, Madani SH, Zare E, Kansestani AN, Hashemiah AH. Kaposi's sarcoma after kidney transplantation: a 21-years experience. Int J Hematol Oncol Stem Cell Res. 2013;7(4):29–33.

  11. Anderson MA, Ying T, Wyburn K, et al. Transplant-associated penile Kaposi sarcoma managed with single agent paclitaxel chemotherapy: a case reportBMC Urol. 2021;21:87. doi:10.1186/s12894-021-00855-y

  12. El-Mallawany NK, Villiera J, Kamiyango W, et al. Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related diseaseInfect Agents Cancer. 2w018;13:33. doi:10.1186/s13027-018-0207-4

  13. McTighe S, Rivard S, Letizia A, Logemann N, Sulit D, Marquart J. Recommendations for counseling and education of service members on endemic African cutaneous Kaposi sarcoma: a case studyMilitary Med. 2018;183:7-8. doi:10.1093/milmed/usx218

  14. Akanle O, Adesina JO. Health and diseases in Africa. Develop Africa. 2018;71:207–26. doi:10.1007/978-3-319-66242-8_12

  15. Armyra K, Kouris A, Zanthinaki A, Stratigos A, Potouridou I. Familial Kaposi's sarcoma: a report of five cases from Greece, Case Rep Dermatol Med. 2014;2014:671631. doi:10.1155/2014/671631

  16. Herout S, Mandorfer M, Breitenecker F, et al. Impact of early initiation of antiretroviral therapy in patients with acute HIV infection in Vienna, Austria. PLoS ONE. 2016;11(4):e0152910. doi:10.1371/journal.pone.0152910

  17. Centers for Disease Control and Prevention. Statistics overview: HIV surveillance report.

  18. Marcus JL, Chao CR, Leyden WA, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to careJ Acquired Immune Defic Syndr. 2016;73(1):39-46. doi:10.1097/QAI.0000000000001014

By James Myhre & Dennis Sifris, MD
Dennis Sifris, MD, is an HIV specialist and Medical Director of LifeSense Disease Management. James Myhre is an American journalist and HIV educator.